Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
3 Stocks That Might Be Priced Below Their Estimated Intrinsic Value

In This Article:

As the U.S. stock market experiences a slight rebound, with major indices like the S&P 500 and Nasdaq Composite snapping their recent losing streaks, investors are keenly observing economic indicators and corporate earnings for signs of stability. In this environment, identifying stocks that may be priced below their intrinsic value can offer potential opportunities for those looking to capitalize on market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name

Current Price

Fair Value (Est)

Discount (Est)

SouthState (NYSE:SSB)

$99.63

$193.86

48.6%

Argan (NYSE:AGX)

$132.20

$264.33

50%

MINISO Group Holding (NYSE:MNSO)

$20.69

$41.15

49.7%

Atour Lifestyle Holdings (NasdaqGS:ATAT)

$30.63

$59.48

48.5%

Northwest Bancshares (NasdaqGS:NWBI)

$12.40

$24.55

49.5%

Old National Bancorp (NasdaqGS:ONB)

$23.40

$45.50

48.6%

Cadre Holdings (NYSE:CDRE)

$33.42

$65.21

48.7%

Array Technologies (NasdaqGM:ARRY)

$6.86

$13.50

49.2%

Albemarle (NYSE:ALB)

$77.53

$151.62

48.9%

DoubleVerify Holdings (NYSE:DV)

$21.59

$42.15

48.8%

Click here to see the full list of 182 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Here we highlight a subset of our preferred stocks from the screener.

Lantheus Holdings

Overview: Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases globally with a market cap of approximately $5.57 billion.

Operations: Lantheus Holdings generates revenue through its development, manufacturing, and commercialization of diagnostic and therapeutic products aimed at aiding clinicians in diagnosing and treating cardiovascular, oncological, and other medical conditions worldwide.

Estimated Discount To Fair Value: 47.9%

Lantheus Holdings, trading at US$93.25, is significantly undervalued with a fair value estimate of US$178.93. Analysts forecast its earnings to grow 19.8% annually, outpacing the U.S. market's 14.2%. Despite slower revenue growth at 11.4%, it still surpasses the market average of 8.8%. Recent guidance indicates revenue between US$1.545 billion and US$1.610 billion for 2025, following sales of US$1.53 billion in 2024 and strategic acquisitions enhancing its radiopharmaceutical capabilities.

NasdaqGM:LNTH Discounted Cash Flow as at Feb 2025
NasdaqGM:LNTH Discounted Cash Flow as at Feb 2025

Intuit

Overview: Intuit Inc. offers financial management, compliance, and marketing products and services in the United States with a market cap of approximately $155.33 billion.